Roger's 1998 Short Picks Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Roger's 1998 Short Picks

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bob Trocchi who wrote (9596)	6/3/1998 12:03:00 PM
From: Peter V	Read Replies (3) of 18691

Hey Bob, looks like ZONA heading your way today. Why the movement? Saw this tidbit, but it didn't look damaging, unless you figure out that there is only a 15 percent increase in the number of patients that are actually helped by the drug (53% of patients taking drug vs. 38% of patients taking placebo acheive same results), but I didn't think the market was that smart: biz.yahoo.com -- Zonagen Inc. (ZONA - news) said Tuesday its anti-impotence drug Vasomax was ''well-tolerated'' during a phase III clinical study, producing nasal congestion in some patients. The company said in a statement that 51 percent of patients taking oral phentolamine, or Vasomax, were able to achieve penetration 75 percent of the time on a dose of 40 mg. The company said 53 percent of patients taking an 80 mg dose achieved penetration 75 percent of the time. Thirty-eight percent of patients taking a placebo were able to achieve penetration 75 percent of the time. Zonagen shares closed at 36-12/16. --------------------------------------------------------------------------------

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next